3-bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine | 1263378-90-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• 英文别名: 3-Bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• CAS: 1263378-90-0
• 化学式: C₆H₈BrN₃
• 分子量: 202.054
• InChiKey: UXJVCOJMZKUACU-UHFFFAOYSA-N

物化性质

• 沸点：
  325.8±42.0 °C(Predicted)
• 密度：
  1.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 在 dipotassium hydrogenphosphate 、 双(三环己基膦)二氯化钯 、 甲酸 、 XPhos Pd G2 、 potassium acetate 作用下， 以 1,4-二氧六环 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 48.0h， 生成 tert-butyl ((1R,3S)-3-((5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)pyridin-2-yl)-carbamoyl)cyclohexyl)carbamate
  参考文献：
  名称：

  Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

  摘要：

  A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

  DOI：

  10.1021/acs.jmedchem.0c01754
• 作为产物：
  描述：

  3-溴4H,5H,6H,7H-吡唑并[1,5-a]吡嗪-5-羧酸叔丁酯 以 乙腈 为溶剂， 300.0 ℃ 、10.0 MPa 条件下， 以94%的产率得到3-bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
  参考文献：
  名称：

  流动中的高温Boc脱保护及其在多步反应序列中的应用

  摘要：

  描述了使用高温流动反应器的简化的Boc脱保护。该系统使用乙腈作为溶剂，无需使用酸性条件或进行额外的后处理即可在数分钟内定性获得各种脱保护底物。还展示了流中高效的多步反应序列，其中步骤之间无需萃取或分离。

  DOI：

  10.1021/acs.orglett.6b00378

文献信息

• MTA-Cooperative PRMT5 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210078994A1

  公开（公告）日：2021-03-18

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180072717A1

  公开（公告）日：2018-03-15

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中R 1 ，R 2 ，X，Y和HET如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• High-Temperature Boc Deprotection in Flow and Its Application in Multistep Reaction Sequences
  作者：Andrew R. Bogdan、Manwika Charaschanya、Amanda W. Dombrowski、Ying Wang、Stevan W. Djuric

  DOI：10.1021/acs.orglett.6b00378

  日期：2016.4.15

  qualitative yield of a wide variety of deprotected substrates within minutes using acetonitrile as the solvent and without the use of acidic conditions or additional workups. Highly efficient, multistep reaction sequences in flow are also demonstrated wherein no extraction or isolation was required between steps.

  描述了使用高温流动反应器的简化的Boc脱保护。该系统使用乙腈作为溶剂，无需使用酸性条件或进行额外的后处理即可在数分钟内定性获得各种脱保护底物。还展示了流中高效的多步反应序列，其中步骤之间无需萃取或分离。
• [EN] SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES<br/>[FR] DIHYDROPYRAZOLO[4,3-B]INDOLES SUBSTITUÉES DANS LES POSITIONS 1 ET 4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014039831A1

  公开（公告）日：2014-03-13

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  本公开涉及式（1）的化合物及其药用盐，其中L、R1、R2、R3、R4、R5、R6和R7在规范中定义。本公开还涉及制备式1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与MetAP2相关的肥胖和相关疾病、紊乱和病况的用途。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014078802A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

  本发明提供了化合物的公式I：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物用于治疗、预防、抑制、改善或根除由疟原虫引起的疾病的病理学和/或症状学的方法，例如疟疾。